Biopsy

EU5 Biopsy Procedures Outlook Report 2020: Breast Biopsy Procedures, Colorectal Biopsy Procedures, Leukemia Biopsy Procedures and Others 2015-2025 - ResearchAndMarkets.com

Friday, January 15, 2021 - 10:47am

2.1 What Is This Report About?

Key Points: 
  • 2.1 What Is This Report About?
  • 4.1.6 Other Indications Biopsy Procedures, France, 2015-2025
    5.1.6 Other Indications Biopsy Procedures, Germany, 2015-2025
    6.1.6 Other Indications Biopsy Procedures, Italy, 2015-2025
    7.1.6 Other Indications Biopsy Procedures, Spain, 2015-2025
    8.1.6 Other Indications Biopsy Procedures, United Kingdom, 2015-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210115005209/en/

ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint® 2.0 Software in Europe

Thursday, January 14, 2021 - 9:05pm

The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain.

Key Points: 
  • The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain.
  • ClearPoint offers a stereotactic system based on MRI localization with an MRI compatible frame.
  • We were delighted to support the talented team at Rigshospitalet during the first European procedure with our latest ClearPoint System, commented Matt Rabon, Clinical and Business Development Manager, EMEA.
  • Expanding into Europe fulfills our strategic mission to become the premier global therapy delivery partner in the Neuro space.

DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry

Thursday, January 14, 2021 - 9:30pm

Melanoma is a life-threatening skin cancer where early detection and intervention can significantly improve clinical outcomes and eliminate disease.

Key Points: 
  • Melanoma is a life-threatening skin cancer where early detection and intervention can significantly improve clinical outcomes and eliminate disease.
  • The study, Genomic Atypia to Enrich Melanoma Positivity in Biopsied Lesions: Gene Expression and Pathology Findings A Large U.S.
  • Registry, reports that lesions biopsied based on genomic atypia criteria identified by the PLA were associated with a nearly five-fold enrichment of melanoma in the patient specimens compared to those biopsied based solely on visual assessment criteria.
  • This large, year-long registry study conducted in the U.S. included 90 providers across 53 dermatology offices and assessed 3,418 pigmented lesions clinically suspicious for melanoma using the PLA.

Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer

Thursday, January 14, 2021 - 1:05pm

The presentations will cover the use of Guardant Healths liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.

Key Points: 
  • The presentations will cover the use of Guardant Healths liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.
  • It is increasingly becoming evident that the value of our liquid biopsy in advanced cancer extends beyond simply tumor mutation profiling.
  • The data presented further demonstrates the value of assessing molecular response to treatment, ushering in a new age of adaptive management of disease progression, said Helmy Eltoukhy, Guardant Health CEO.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients.

NeoDynamics will be granted another European patent for its pulse biopsy tools

Thursday, January 14, 2021 - 7:41am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

NeoDynamics will be granted another European patent for its pulse biopsy tools

Thursday, January 14, 2021 - 7:40am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics Solutions

Wednesday, January 13, 2021 - 1:02pm

InterVenn Biosciences , the leader in glycoproteomics, today announced the accomplishment of multiple milestones in advancing the worlds first glycoproteomics-based LDT(Lab-Developed Test).

Key Points: 
  • InterVenn Biosciences , the leader in glycoproteomics, today announced the accomplishment of multiple milestones in advancing the worlds first glycoproteomics-based LDT(Lab-Developed Test).
  • The companys first diagnostic product, a noninvasive liquid biopsy test for ovarian cancer, will have final data from its initial clinical trial, V.O.C.A.L.
  • , in the first half of 2021; and InterVenns on-site laboratory has recently received CLIA certification to make its tests available to the medical community.
  • In the course of planned 2021 studies, InterVenn will continue to engage in a range of partnerships to develop predictive and companion diagnostic claims.

Strata Oncology Announces Personalized Recurrence Monitoring Trial

Wednesday, January 13, 2021 - 12:30pm

"The Sentinel Trial will support the validation of our personalized recurrence monitoring assay for patients with solid tumors in a diverse population," said Dan Rhodes , PhD, co-founder and Chief Executive Officer, Strata Oncology.

Key Points: 
  • "The Sentinel Trial will support the validation of our personalized recurrence monitoring assay for patients with solid tumors in a diverse population," said Dan Rhodes , PhD, co-founder and Chief Executive Officer, Strata Oncology.
  • The Sentinel Trial will pair simultaneous DNA and RNA tissue-based molecular profiling with liquid biopsy-based recurrence monitoring.
  • Strata Oncology recently made StrataNGSTM broadly available in the U.S. based on its experience processing more than 40,000 tissue specimens from patients with advanced cancer through the Strata Trial.
  • Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer.

DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines

Tuesday, January 12, 2021 - 9:01pm

The NCCN Clinical Practice Guidelines in Oncology (the NCCN Guidelines) for cutaneous melanoma recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma.

Key Points: 
  • The NCCN Clinical Practice Guidelines in Oncology (the NCCN Guidelines) for cutaneous melanoma recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma.
  • The recommendation for pre-diagnostic non-invasive genomic patch testing can be found in the latest edition, NCCN Guidelines Version 1.21, Melanoma: Cutaneous, section ME-11, Common Follow-Up Recommendations for All Patients.
  • The updated guidance now states: Pre-diagnostic noninvasive genomic patch testing may also be helpful to guide biopsy decisions.
  • I laud the NCCN for recognizing the value of non-invasive genomic patch testing and including it in the current guidelines.

Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers

Tuesday, January 12, 2021 - 1:00pm

BALTIMORE, Jan. 12, 2021 /PRNewswire/ --Delfi Diagnostics, Inc., a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection, has raised $100 million in Series A funding.

Key Points: 
  • BALTIMORE, Jan. 12, 2021 /PRNewswire/ --Delfi Diagnostics, Inc., a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection, has raised $100 million in Series A funding.
  • "The Delfi team has a unique and groundbreaking approach to early detection of cancer," said Rishi Gupta, Partner at OrbiMed.
  • Delfi is developing a new class of liquid biopsy for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells.
  • Founded in 2019, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer across multiple tumor types.